Terms: = Pancreatic cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Diagnosis
25 results:
1. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (pd-l1) in pancreatic cancer.
Pourali G; Zafari N; Velayati M; Mehrabadi S; Maftooh M; Hassanian SM; Mobarhan MG; Ferns GA; Avan A; Khazaei M
Curr Drug Targets; 2023; 24(17):1335-1345. PubMed ID: 38053355
[TBL] [Abstract] [Full Text] [Related]
2. Global Trends and Prospects Regarding Exosomes in cancer Immunology Research Over the Past 10 Years.
Xia D; Wu R; Wang S; Chen G; Lu Y; Zhao L
Technol Cancer Res Treat; 2023; 22():15330338231199892. PubMed ID: 37990510
[No Abstract] [Full Text] [Related]
3. Role of Immune Microenvironment in pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
De Simoni O; Dal Santo L; Scarpa M; Munari G; Spolverato YC; Scapinello A; Lonardi S; Soldà C; Bergamo F; Fantin A; Bardini R; Pilati P; Fassan M; Gruppo M
Curr Oncol; 2023 Jun; 30(6):5515-5528. PubMed ID: 37366900
[TBL] [Abstract] [Full Text] [Related]
4. The prognostic role of epidermal growth factor receptor mutation in completely resected ampullary adenocarcinoma.
Varol U; Cakır E; Aktas S; Altun ZS; Dilek FH; Butun O; Salman T; Unlu AGD; Alacacioglu A; Somali I
Pol J Pathol; 2023; 74(1):18-28. PubMed ID: 37306349
[TBL] [Abstract] [Full Text] [Related]
5. A case report of anterior mediastinal signet ring cell carcinoma.
Liu S; Zhao A; Mao M
Medicine (Baltimore); 2022 Dec; 101(48):e32202. PubMed ID: 36482538
[TBL] [Abstract] [Full Text] [Related]
6. Case report: Two pd-l1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases.
Shang L; Li P; Fan J; Zhao C; Niu X; Bian Q; Yuan Z; Kong Y; Zhu T; Xu B; Dong J; Xiang H
Front Immunol; 2022; 13():946266. PubMed ID: 36203575
[TBL] [Abstract] [Full Text] [Related]
7. Targeting Tumor Microenvironment in Liver cancers: Rationale, Current Progress, and Future Perspective.
Duda DG
Keio J Med; 2022; 71(3):71. PubMed ID: 36155490
[TBL] [Abstract] [Full Text] [Related]
8. Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma.
Ali SMA; Adnan Y; Ali SM; Ahmad Z; Chawla T; Farooqui HA
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2279-2292. PubMed ID: 36066622
[TBL] [Abstract] [Full Text] [Related]
9. Stocky/Packed Pancreas: A Case of Focal Drug-Induced Acute Pancreatitis Mimicking cancer.
Di Serafino M; Ronza R; D'Auria D; Fiorentino R; Arundine D; De Leone A; Picascia S; Martino A; Crolla E; Campione S; Guida G; Molino C; Riccardi F; Romano L
Tomography; 2022 Aug; 8(4):2073-2082. PubMed ID: 36006072
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected pancreatic Adenocarcinoma.
Başoğlu T; Akar KE; Bağcı P; Akgül Babacan N; Öztürk MA; Öztürk FE; Demircan NC; Arikan R; Akın Telli T; Ercelep Ö; Dane F; Yumuk PF
Balkan Med J; 2022 Jan; 39(1):12-20. PubMed ID: 34928235
[TBL] [Abstract] [Full Text] [Related]
11. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of pancreatic cancer.
Markov SD; Caffrey TC; O'Connell KA; Grunkemeyer JA; Shin S; Hanson R; Patil PP; Shukla SK; Gonzalez D; Crawford AJ; Vance KE; Huang Y; Eberle KC; Radhakrishnan P; Grandgenett PM; Singh PK; Madiyalakan R; Daniels-Wells TR; Penichet ML; Nicodemus CF; Poole JA; Jaffee EM; Hollingsworth MA; Mehla K
Mol Cancer Ther; 2021 Dec; 20(12):2457-2468. PubMed ID: 34625505
[TBL] [Abstract] [Full Text] [Related]
12. Antitumor immune response is associated with favorable survival in GEP-NEN G3.
Rosery V; Reis H; Savvatakis K; Kowall B; Stuschke M; Paul A; Dechêne A; Yang J; Zhao B; Borgers A; Kasper S; Schuler M; Cheung PF; Siveke JT
Endocr Relat Cancer; 2021 Sep; 28(10):683-693. PubMed ID: 34472429
[TBL] [Abstract] [Full Text] [Related]
13. Serum Soluble pd-l1, PD-L2, and b7-h5 as Potential Diagnostic Biomarkers of Human pancreatic cancer.
Wu W; Xia X; Cheng C; Niu L; Wu J; Qian Y
Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107622
[TBL] [Abstract] [Full Text] [Related]
14. Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing pd-l1 Expression in PDAC.
Zhou KX; Huang S; Hu LP; Zhang XL; Qin WT; Zhang YL; Yao LL; Yu Y; Zhou YQ; Zhu L; Ji J; Zhang ZG
J Immunol Res; 2021; 2021():6694392. PubMed ID: 33728352
[TBL] [Abstract] [Full Text] [Related]
15. Mechanisms Governing Immunotherapy Resistance in pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract] [Full Text] [Related]
16. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract] [Full Text] [Related]
17. pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor pd-l1 Score.
Copur MS; Vargas L; Wedel W; Merani S; Cushman-Vokoun A; Drincic A
Oncology (Williston Park); 2020 Dec; 34(12):548-552. PubMed ID: 33395496
[TBL] [Abstract] [Full Text] [Related]
18. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
[TBL] [Abstract] [Full Text] [Related]
19. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
Byun DJ; Braunstein R; Flynn J; Zheng J; Lefkowitz RA; Kanbour S; Girotra M
Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
[TBL] [Abstract] [Full Text] [Related]
20. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.
Marchand L; Disse E; Dalle S; Reffet S; Vouillarmet J; Fabien N; Thivolet C; Cugnet-Anceau C
Acta Diabetol; 2019 Dec; 56(12):1239-1245. PubMed ID: 31423559
[TBL] [Abstract] [Full Text] [Related]
[Next]
